1. Hales CM, Carroll MD, Fryar CD, et al: Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief, no 360. Hyattsville, MD: National Center for Health Statistics, 2020. 2. Tappy L. Metabolic consequences of overfeeding in humans. Curr Opin Clin Nutr Metab Care. 2004;7(6):623-62. 3. Бойцов С.А., Баланова Ю.А., Шальнова С.А., Деев А.Д., Артамонова Г.в., Гатагонова Т.М. и др. Артериальная гипертония среди лиц 25—64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2014;13(4):4-14. doi:10.15829/1728-8800-2014-4-4-14. 4. Cani PD, Delzenne NM. Gut microflora as a target for energy and metabolic homeostasis//Curr Opin Clin Nutr Metab Care. 2007;10(6):729-734. doi:10.1097/MCO.0b013e3282efdebb 5. Xu J, Gordon JI. Inaugural Article: Honor thy symbionts. Proc Natl Acad Sci USA. 2003;100(18):10452-10459. doi:10.1073/pnas.1734063100 6. Leser TD. Better living through microbial action: the benefits of the mammalian gastrointestinal microbiota on the host. Environ Microbiol. 2009;11:2194-2206. doi:10.1111/j.1462-2920.2009.01941. 7. Драпкина О.М., Корнеева О.Н. Кишечная микробиота и ожирение. Патогенетические взаимосвязи и пути нормализации кишечной микрофлоры// Терапевтический архив 9, 2016. С. 135-142. 8. Драпкина О.М., Корнеева О.Н., Ивашкин В.Т. Микрофлора кишечника и ожирение. Российские медицинские вести. 2014;19 (2): 12-16. doi: http: //medlib.dp.gov.ua:8087/jirbis2/images/fond_publications/rossiyskie_medicinskie_vesti/rmv214.pdf 9. Al-Attas O, Al-Daghri N, Al-Rubeaan K. Changes in endotoxin levels in T2 DM subjects on anti-diabetic therapies. Cardiovasc Diabet. 2009;8:20-29. doi:10.1186/1475-2840-8-20 10. Rodes L, Khan A, Paul A, Coussa-Charley M, Marinescu D, Tomaro-Duchesneau C et al. Effect of probiotics Lactobacillus and Bifidobacteriumon gut-derived lipopolysaccharides and inflammatory cytokines: an in vitro study using a human colonic microbiota model. J Microbiol Biotechnol. 2013;23:518-526. doi:10.4014/jmb.1205.05018. 11. Cani PD, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des. 2009;15:1546- 1558. doi:10.2174/138161209788168164 12. Tsukumo DM, Carvalho BM, Carvalho-Filho MA, Saad MJ. Translational research into gut microbiota: new horizons in obesity treatment. Arq Bras Endocrinol Metab. 2009;53(2):139-144. doi:10.1590/S0004-27302009000200004 13. Lee HY, Park JH, Seok SH et al. Human originated bacteria, Lactobacillus rhamnosus PL60, produce conjugated linoleic acid and show anti-obesity effects in diet-induced obese mice. Biochim Biophys Acta. 2006;1761(7):736-744. doi:10.1590/s0004-27302009000200004 14. Lee SJ, Bose S, Seo JG, Chung WS, Lim CY, Kim H. The effects of co-administration of probiotics with herbal medicine on obesity, metabolic endotoxemia and dysbiosis: A randomized doubleblind controlled clinical trial. Clin Nutr. 2014;33(6)973-81. doi:10.1016/j.clnu.2013.12.006. 15. Lee SJ, Bose S, Seo JG, Chung WS, Lim CY, Kim H. The effects of co-administration of probiotics with herbal medicine on obesity, metabolic endotoxemia and dysbiosis: A randomized doubleblind controlled clinical trial. Clin Nutr. 2014;33(6)973-81. doi:10.1016/j.clnu.2013.12.006. 16. Vallianou N.G., Kounatidis D., Tsilingiris D, Panagopoulos F, Christodoulatos G. S., Evangelopoulos A., Karampela I., Dalamaga M. The Role of Next-Generation Probiotics in Obesity and Obesity-Associated Disorders: Current Knowledge and Future Perspectives// Int. J. Mol. Sci. 2023, 24, 6755. https://doi.org/10.3390/ijms24076755.